Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$64.70 USD
+0.85 (1.33%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $64.62 -0.08 (-0.12%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$64.70 USD
+0.85 (1.33%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $64.62 -0.08 (-0.12%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum A VGM
Zacks News
Gilead (GILD), Arcus Announce Results From Mid-Stage NSCLC Study
by Zacks Equity Research
Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.
Top Stock Reports for FEMSA, NextEra Energy & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Fomento Economico Mexicano, S.A.B. de C.V. (FMX), NextEra Energy, Inc. (NEE) and Sanofi (SNY).
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Pfizer's (PFE) COVID-19 Oral Treatment Gets FDA Nod in Adults
by Zacks Equity Research
Per the FDA, Pfizer's (PFE) Paxlovid is the first oral antiviral pill approved in the United States to treat COVID-19 in adults. The drug was granted emergency use authorization by the FDA in 2021.
Gilead's (GILD) Veklury Gets Positive CHMP View for Extended Use
by Zacks Equity Research
Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.
Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEY
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases
by Zacks Equity Research
Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.
Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CLRG
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Is SPDR Russell 1000 Yield Focus ETF (ONEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEY
Is IQ Chaikin U.S. Large Cap ETF (CLRG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CLRG
Biotech ETFs Pop on M&A Resurgence
by Neena Mishra
2023 could be a year of heightened biotech dealmaking activity
Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge
by Zacks Equity Research
Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.
Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of -15.95% and 0.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More
by Ahan Chakraborty
Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.
Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Big Tech Earnings & Economic Numbers: 3 Ways to Survive the Week Ahead
by Andrew Rocco
Many of the FANG stocks are slated to report earnings this week. Today, we will lay out how investors can best navigate the action packed week ahead.
Will HIV and Oncology Propel Gilead's (GILD) Q1 Earnings?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its first-quarter 2023 results.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $83.78, marking a +0.18% move from the previous day.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $82.16 in the latest trading session, marking a -0.46% move from the prior day.
Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPYD
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE